Target intelligence / Profile preview

ADP-ribosylation factor-like protein 4C (ARL4C)

Target
ARL4C
Molecular classification
Small GTPase, ARF family (ADP-ribosylation factor-related GTP-binding protein), Ras superfamily, Actin cytoskeleton regulator
01

Overview

ADP-ribosylation factor-like protein 4C (ARL4C) is a member of the ARF family of small GTP-binding proteins within the Ras superfamily, involved in the regulation of actin cytoskeleton dynamics, cell morphology, migration, and membrane trafficking[1][5]. It localizes to cell membranes, cytoplasm, and nucleus, exhibits unusually high guanine nucleotide exchange rates, and interacts with regulators such as filamin-A and Cdc42 to drive filopodia formation and motility[5]. ARL4C participates in lipid and cholesterol metabolism through LXR-mediated pathways and is implicated in tumor progression, primarily by promoting cancer cell proliferation, migration, and invasion[1][3][5]. Elevated ARL4C expression is associated with cancer aggressiveness, making it both a potential biomarker and a therapeutic target candidate, particularly in renal cell carcinoma and atherosclerosis[1][2][3].

Other names
ARL4CARF-like 7ARL7LAKADP-ribosylation factor-like protein 7ADP-ribosylation factor-like protein LAKADP-ribosylation factor-like 4C
02

Mechanism of action

LXR agonists modulate ARL4C expression and thereby promote cholesterol efflux, alter lipid metabolism. Likely indirect inhibition of cancer cell growth/migration via ARL4C suppression; no direct inhibition described.

03

Biological functions

Signal transductionRegulation of cell morphologyRegulation of cell migrationCytoskeletal remodelingVesicular/membrane traffickingRegulation of cell proliferationBranching morphogenesis (especially in kidney development)Cholesterol efflux and metabolism
04

Disease associations

Cancer (notably renal cell carcinoma, oral squamous cell carcinoma)Atherosclerosis/metabolic disorders involving cholesterolPotential roles in other epithelial tumorigenesis and organ development
05

Safety considerations

No specific safety concerns described; targeting ARL4C may affect cholesterol homeostasis or cytoskeletal integrity, which could impact multiple tissues
06

Interacting drugs

Liver X receptor agonists (e.g., LXR623)
07

Biomarkers

ARL4C expression (mRNA/protein) as a biomarker for cancer cell proliferation, migration, invasion (e.g., in renal cell carcinoma)ARL4C as a potential biomarker for cholesterol efflux capacity and atherosclerosis risk

Beyond the preview

Go deeper on ADP-ribosylation factor-like protein 4C (ARL4C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADP-ribosylation factor-like protein 4C (ARL4C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call